GOPO® has been extensively studied in scientifically robust clinical trials involving more than 400 patients with chronic joint conditions. The treatment has produced significant and consistent pain relief and improved joint function in patients with both osteoarthritis (OA) and rheumatoid arthritis (RA).
A number of independently-conducted clinical trials have shown that GOPO® consistently reduces pain associated with chronic joint conditions. In one randomised, double-blind, placebo-controlled study involving 94 patients with osteoarthritis of the hip or knee, 8 out of 10 patients reported a significant reduction in pain after just 3 weeks of GOPO® treatment.
In another randomized, double-blind, placebo-controlled study involving 89 patients with rheumatoid arthritis: GOPO® significantly reduced the number of tender and swollen joints.
In one trial, pain associated with OA has also been alleviated to such an extent with GOPO® that the use of ‘rescue medication’ (e.g. paracetamol, opioids) significantly declined with GOPO® treatment.
Several clinical trials have confirmed that GOPO® improves joint mobility and reduces disability. In studies, GOPO®:
Studies in the laboratory have demonstrated that GOPO® can switch off certain genes responsible for producing proteins and enzymes that have been implicated in inflammatory joint destruction and switch on genes that help to produce collagen and cartilage, which are essential components of a healthy joint. This suggests that GOPO® may protect cartilage cells and help to rebuild joint tissues.
A meta-analysis of three large, randomized controlled trials conducted using GOPO® in 287 OA patients confirmed that GOPO® offers significant and robust joint pain relief, enabling a reduction in the consumption of painkillers.
A comparison of pain effect size scores in these studies with those published for paracetamol and glucosamine suggests that GOPO® may be more effective than paracetamol and glucosamine.